Insulet Corporation
Data as of April 18, 2026
Key Metrics
Market Cap
$14.34B
P/E Ratio
58.38
P/B Ratio
9.46
Dividend Yield
—
Return on Equity
0.18%
Debt / Equity
66.18
Insider Ownership
0.31%
Institutional Own.
105.44%
Employees
5,400
Sector & Industry
Sector
Healthcare
Industry
Medical Devices
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Ownership Snapshot
Source: Yahoo Finance / SEC filings. For full details, see the Holdings page.